Acupuncture or Metformin for Insulin Resistance in Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial

Who is this study for? Adult female patients with polycystic ovary syndrome
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other, Device, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The hypothesis is that acupuncture is equally effective as metformin (both treatments combined with lifestyle management) in improving whole body glucose homeostasis in insulin resistant women with polycystic ovary syndrome (PCOS), and that both are superior to lifestyle management alone. The investigators hypothesize that acupuncture and metformin induce ovulation and improve hyperandrogenism, as well as health related quality of life (HRQoL) and symptoms of anxiety and depression. Although equally effective (acupuncture and metformin), the investigators hypothesize that acupuncture is associated with less negative side-effects. The investigators also hypothesize that these treatments have the potential to restore epigenetic and molecular alterations in target tissues (endometrial-, adipose-, and skeletal muscle tissue) and thus have the potential to prevent the development of type 2 diabetes (T2D).

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 40
Healthy Volunteers: t
View:

• Age 18 to 40 years

• Body mass index (BMI) ≥25 to ≤40 given that 95% of all women with PCOS with a BMI ≥25 are insulin resistant (71,72).

• PCOS diagnosis according to Rotterdam criteria 2003 (73), with at least two of the following three symptoms: Clinical signs of hyperandrogenism (hirsutism or acne); oligo/amenorrhea; and/or polycystic ovaries (PCOS). Hirsutism is defined as a self-reported Ferriman-Gallwey (FG) score ≥8 (≥5 Asian) (74,75). Acne is defined by a positive response to the question Do you have acne? Oligomenorrhea is defined as an intermenstrual interval \>35 days and \<8 menstrual bleedings in the past year. Amenorrhea as \<3 cycles per year. PCO is defined by transvaginal ultrasound with ≥12 follicles 2-9 mm and/or ovarian volume ≥10 ml in one or both ovaries.

• Willing to sign the consent form.

⁃ Controls should have BMI \>25 to \<40, regular cycles with 28 days ± 2 days, and no signs of hyperandrogenism. They are excluded if they have menstrual irregularities, signs of hyperandrogenism (FG \>4), or evidence of PCO morphology on ultrasound.

Locations
Other Locations
China
Peking University
RECRUITING
Beijing
Sweden
Karolinska University Hospital
RECRUITING
Stockholm
Contact Information
Primary
Elisabet Stener-Victorin, PhD
elisabet.stener-victorin@ki.se
+46705643655
Backup
Berit Legerstam, Study nurse
berit.legerstam@karolinska.se
+46851773782
Time Frame
Start Date: 2015-12
Estimated Completion Date: 2026-06
Participants
Target number of participants: 303
Treatments
Active_comparator: Lifestyle management
All women will receive lifestyle management instructions at the baseline visit, before randomization.
Active_comparator: Acupuncture + lifestyle management
Three treatment per week (4 weeks) and thereafter 2 times per week during 12 weeks.
Active_comparator: Metformin + lifestyle management
Oral metformin 500 mg three times daily, in total 1500 mg per day.
Sponsors
Collaborators: Karolinska University Hospital, Peking University
Leads: Karolinska Institutet

This content was sourced from clinicaltrials.gov